Supernus Pharmaceuticals Inc (SUPN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jack A. Khattar
Employees:
448
1550 E GUDE DR, ROCKVILLE, MD 20850
301-838-2500

Supernus Pharmaceuticals, Inc. develops and commercializes products for the treatment of central nervous system. It also develops multiple product candidates in psychiatry to address the large market opportunity in the treatment of attention deficit hyperactivity disorder, or ADHD, including ADHD patients with impulsive aggression. The company markets their products in the U.S. through their own focused sales force targeting specialty physicians and seek strategic collaborations with other pharmaceutical companies to license their products outside the U.S. Its neurology portfolio consists of Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended release topiramate). The company's psychiatry product candidates include SPN-810 (molindone hydrochloride), SPN-812 and SPN-809. Supernus Pharmaceuticals was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Data derived from most recent annual or quarterly report
Market Cap 1.601 Billion Shares Outstanding53.146 Million Avg 30-day Volume 379.368 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 34.29 / 17.2 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from SUPN instead.

View recent insider trading info

Funds Holding SUPN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SUPN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DEC TIMOTHY C SENIOR VICE-PRESIDENT & CFO

  • Officer
0 2021-08-23 2

SIEBERT JOHN M

  • Director
75,953 2021-08-11 2

KHATTAR JACK A. PRESIDENT, CEO

  • Officer
  • Director
1,618,916 2021-07-30 3

MARTIN TAMI TILLOTSON SR. V.P., REGULATORY AFFAIRS

  • Officer
188,277 2021-04-13 2

NEWHALL CHARLES W III

  • Director
109,096 2021-02-19 1

GEMAYEL GEORGES

  • Director
16,798 2021-02-19 1

HUDSON FREDERICK M.

  • Director
29,628 2021-02-19 1

KELLY JAMES PATRICK EXECUTIVE VICE-PRESIDENT & CFO

  • Officer
15,000 2021-02-19 1

BHATT PADMANABH P. SR. VP OF IP, CSO

  • Officer
17,000 2021-02-19 1

BARLOW CARROLEE

  • Director
16,798 2021-02-19 1

MOTTOLA FRANK SVP, QUALITY, GMP OPS. & IT

  • Officer
23,839 2021-02-19 1

RUBIN JONATHAN SVP, CHIEF MEDICAL OFFICER

  • Officer
25,000 2021-02-19 2

SCHWABE STEFAN K.F. EXECUTIVE VICE PRESIDENT & CMO

  • Officer
2,772 2020-12-21 2

PATRICK GREGORY S SR. VP CHIEF FINANCIAL OFFICER

  • Officer
44,463 2020-11-09 2

LENGAUER CHRISTOPH

  • Director
0 2019-04-17 0

PINSCHEWER DAVID CHIEF SCIENTIFIC OFFICER

  • Officer
0 2019-04-17 0

MATUSHANSKY IGOR CHIEF MEDICAL OFFICER

  • Officer
0 2019-04-17 0

VAUGHN VICTOR SR. VP OF SALES & MARKETING

  • Officer
9,344 2018-04-18 0

NUERGE WILLIAM A.

  • Director
23,750 2017-06-13 0

BARRETT M JAMES

  • Director
212,710 2016-03-16 0

BARRIS PETER J

  • 10% Owner
No longer subject to file 2015-11-11 0

SANDELL SCOTT D

  • 10% Owner
No longer subject to file 2015-11-11 0

NEW ENTERPRISE ASSOCIATES 11 LP

  • 10% Owner
No longer subject to file 2015-11-11 0

NEA PARTNERS 11 LP

  • 10% Owner
No longer subject to file 2015-11-11 0

KOLLURI KRISHNA KITTU

  • 10% Owner
No longer subject to file 2015-11-11 0

BASKETT FOREST

  • 10% Owner
No longer subject to file 2015-11-11 0

BRYAN JONES W. VP OF BUSINESS DEVELOPMENT

  • Officer
67,980 2015-03-30 0

BIGHAM MICHAEL

  • Director
25,000 2013-03-20 0

ORBIMED ADVISORS LLC

ISALY SAMUEL D

ORBIMED CAPITAL GP II LLC

  • 10% Owner
No longer subject to file 2013-02-12 0

NEW ENTERPRISE ASSOCIATES 11 LP

NEA PARTNERS 11 LP

NEA 11 GP, LLC

BARRIS PETER J

BASKETT FOREST

DRANT RYAN D

KOLLURI KRISHNA KITTU

KRAMLICH C RICHARD

PERRY MARK W

SANDELL SCOTT D

  • 10% Owner
10,641,250 2012-05-04 0

SHEFFERY MICHAEL B

  • Director
6,099,996 2012-05-04 0

ABINGWORTH MANAGEMENT LTD

  • 10% Owner
3,600,000 2012-05-04 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 19:15:03 UTC -0.18 0.25 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 18:45:03 UTC -0.18 0.25 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 18:15:03 UTC -0.18 0.25 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 17:45:03 UTC -0.18 0.25 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 17:15:03 UTC -0.18 0.25 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 16:45:04 UTC -0.18 0.25 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 16:15:03 UTC -0.18 0.25 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 15:45:03 UTC -0.18 0.25 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 15:15:03 UTC -0.18 0.25 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 14:45:03 UTC -0.1809 0.2509 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 14:15:05 UTC -0.1809 0.2509 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 13:45:03 UTC -0.1809 0.2509 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 13:15:03 UTC -0.1809 0.2509 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-26 12:45:03 UTC -0.1809 0.2509 2700000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-25 22:15:03 UTC -0.1809 0.2509 2300000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-25 21:45:03 UTC -0.1809 0.2509 2300000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-25 21:15:03 UTC -0.1809 0.2509 2300000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-25 20:45:03 UTC -0.1809 0.2509 2300000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-25 20:15:03 UTC -0.1809 0.2509 2300000
SUPERNUS PHARMACEUTICALS INC SUPN 2021-10-25 19:45:04 UTC -0.1809 0.2509 2300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund SUPN -44000.0 shares, $-1158520.0 2021-07-31 N-PORT

Elevate your investments